DelveInsight’s, “Acne Vulgaris Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the Acne Vulgaris pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Acne Vulgaris Treatment Landscape @ https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight

Key Takeaways from the Acne Vulgaris Pipeline Report

• In April 2026, Integrative Skin Science and Research initiated a study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on the skin will be studied to see how each treatment may affect them and whether they change the profile of the bacteria that is present.
• DelveInsight’s Acne Vulgaris pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Acne Vulgaris treatment.
• The leading Acne Vulgaris Companies such as Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
• Promising Acne Vulgaris Pipeline Therapies such as Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.

Discover groundbreaking developments in Acne Vulgaris Therapies! @ Acne Vulgaris Ongoing Clinical Trials Assessment

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne may appear in adolescence, and it persists through the early thirties. Acne is more common in males than in females. Urban populations are more affected than rural populations. About 20% of the affected individuals develop severe acne, which results in scarring. Some races appear to be more affected than others. Acne occurs by hypersensitivity of the sebaceous glands to a normal circulating level of androgens, which are aggravated by P. acnes and inflammation.

Acne Vulgaris Emerging Drugs Profile

• Berdazimer sodium (SB 204): Pelthos Therapeutics

SB204 is a first-in-class nitric oxide (NO)-releasing topical treatment monotherapy. The Phase 2b study demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at Week 12 with all doses of SB204 compared to vehicle. SB204 demonstrated excellent cutaneous tolerability with no treatment-related serious adverse events in over 400 dosed subjects to date. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.

• DMT310: Dermata Therapeutics

DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.

• GT 20029 : Suzhou Kintor Pharmaceuticals

GT-20029 is a small molecule that works on Androgen receptor degradation enhancer’s mechanism of action. It is administered through topical route as gel/tincture form. The drug candidate acts by targeting androgen receptor and cereblon (CRBN). It is being developed based on PROTAC (Protein Degradation Targeting Chimera) technology. Currently, the drug is in Phase I stage of its development for the treatment of acne vulgaris.

The Acne Vulgaris Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.
• Acne Vulgaris Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acne Vulgaris Unmet Needs

Acne Vulgaris Companies

Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.

Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acne Vulgaris Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in drug development and clinical research @ Acne Vulgaris Market Drivers and Barriers, and Future Perspectives

Scope of the Acne Vulgaris Pipeline Report

• Coverage- Global
• Acne Vulgaris Companies- Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
• Acne Vulgaris Pipeline Therapies- Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.
• Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Acne Vulgaris Pipeline Analysis Today! @ Acne Vulgaris Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Acne Vulgaris: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acne Vulgaris– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Berdazimer sodium (SB 204) : Pelthos Therapeutics
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Early Stage Products (Phase I/II)
12. GT 20029 : Suzhou Kintor Pharmaceuticals
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Acne Vulgaris Key Companies
17. Acne Vulgaris Key Products
18. Acne Vulgaris- Unmet Needs
19. Acne Vulgaris- Market Drivers and Barriers
20. Acne Vulgaris- Future Perspectives and Conclusion
21. Acne Vulgaris Analyst Views
22. Acne Vulgaris Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight